Top Markets
#1 Cortex Cortex +32.42%
#2 龙虾 (Lobster) 龙虾 (Lobster) +30.38%
#3 Akedo Akedo +25.48%
#4 DexNet DexNet +23.19%
#5 Pons Pons +21.68%
#6 wojak wojak +16.75%
#7 APEX APEX +13.93%
#8 OpenEden OpenEden +13.55%
#9 Official Trump Official Trump +11.37%
#10 EXOD EXOD +9.04%
Coin of the day
Cortex Cortex
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Pharma Mar, S.A. Pharma Mar, S.A.

Pharma Mar, S.A.

PHM
Kedudukan dalam Saham #7110
Pharma Mar, S.A., a biopharmaceutical firm established in 1986 and... Pharma Mar, S.A., a biopharmaceutical firm established in 1986 and headquartered in Madrid, Spain, is dedicated to the research, development, production, and global sale of marine-derived bioactive compounds. Its primary focus is oncology, with operations spanning Spain, Italy, Germany, Ireland, the wider European Union, the United States, and other international markets. The company's activities are organized into three key segments: Oncology, Diagnostics, and RNA interference. Among its developed and commercialized treatments are Yondelis, prescribed for soft tissue sarcomas and ovarian cancer; Aplidin, targeting multiple myeloma; and Zepzelca, used for patients with small cell lung cancer. Furthermore, Pharma Mar is advancing PM14, currently in Phase II clinical trials for various solid tumors. Beyond pharmaceuticals, the company manufactures and markets diagnostic kits and is involved in creating therapeutic drugs designed to reduce or silence gene expression.
Harga Saham
$99.16
Disegerakkan terakhir: 2026-08-27
Modal Pasaran
$1.72B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
2.52%
Negara
ES
Perdagangan Pharma Mar, S.A. (PHM)

Kategori

Healthcare
Pendapatan untuk Pharma Mar, S.A. (PHM)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini Pharma Mar, S.A., pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Pharma Mar, S.A. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH